NCT06990269View on ClinicalTrials.gov

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Sponsors
All Listed Sponsors
lead

ADARx Pharmaceuticals, Inc.

INDUSTRY